BioSpace News Archive

The FDA voted six in favor and thirteen against the benefit/risk profile of TLANDO.

BIO President and CEO Jim Greenwood issued the following statement regarding the review of the 340B drug pricing program released by the House Energy & Commerce Committee today:

California Life Sciences Association today issued the following statement applauding Governor Jerry Brown’s 2018 – 2019 California budget proposal that calls for $30 million to be invested in precision medicine research and the establishment of the California Institute to Advance Precision Health and Medicine (CIAPHM).

The Bonnie J. Addario Lung Cancer Foundation and the American Lung Association’s LUNG FORCE welcome the International Association for the Study of Lung Cancer as a new member of the Lung Cancer Patient Registry.

PharMEDium is voluntarily expanding the recall issued on December 27, 2017 to include the below lots of sterile drug products to the hospital/user level due to a lack of assurance of sterility.

GlaxoSmithKline CEO Emma Walmsley is not done reshaping her leadership team as she continues to overhaul the company’s pharmaceutical division.

Investors and analysts, after all, had been speculating, even nagging, on who the company should buy for several years.

GlaxoSmithKline CEO Emma Walmsley is eying a big acquisition to spur revenue growth but is making sure that her company will not overpay.

Valeant’s CEO projects that a $1 billion portfolio of key products will help the drug maker fight debt and exclusivity challenges.

Shares of Diffusion Pharma shot up more than 40 percent Tuesday after the company provided an overview of the company and its Phase III candidate.